These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34377229)

  • 1. Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
    Thangaiyan R; Aljahdali IA; Lent-Moore KY; Liao J; Ling X; Li F
    Am J Transl Res; 2021; 13(7):7458-7474. PubMed ID: 34377229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer.
    Santha S; Ling X; Aljahdali IAM; Rasam SS; Wang X; Liao J; Wang J; Fountzilas C; Li Q; Qu J; Li F
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33217967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.
    Ling X; Wu W; Aljahdali IAM; Liao J; Santha S; Fountzilas C; Boland PM; Li F
    Clin Transl Med; 2022 May; 12(5):e881. PubMed ID: 35604033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
    Ling X; Cao S; Cheng Q; Keefe JT; Rustum YM; Li F
    PLoS One; 2012; 7(9):e45571. PubMed ID: 23029106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple mechanisms involved in a low concentration of FL118 enhancement of AMR-MeOAc to induce pancreatic cancer cell apoptosis and growth inhibition.
    Rabi T; Li F
    Am J Cancer Res; 2018; 8(11):2267-2283. PubMed ID: 30555743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?
    Li F; Ling X; Harris DL; Liao J; Wang Y; Westover D; Jiang G; Xu B; Boland PM; Jin C
    Am J Cancer Res; 2017; 7(2):370-382. PubMed ID: 28337384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?
    Li F
    Am J Cancer Res; 2014; 4(3):304-11. PubMed ID: 24959385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of FL118, a survivin, Mcl-1, XIAP, and cIAP2 selective inhibitor, is highly dependent on its primary structure and steric configuration.
    Zhao J; Ling X; Cao S; Liu X; Wan S; Jiang T; Li F
    Mol Pharm; 2014 Feb; 11(2):457-67. PubMed ID: 24329001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.
    Ling X; Xu C; Fan C; Zhong K; Li F; Wang X
    Cancer Res; 2014 Dec; 74(24):7487-97. PubMed ID: 25512388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of
    Tikum AF; Ketchemen JP; Doroudi A; Nambisan AK; Babeker H; Njotu FN; Fonge H
    J Nucl Med; 2024 Feb; ():. PubMed ID: 38360051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation.
    Tajiknia V; Pinho-Schwermann M; Srinivasan PR; Hernandez Borrero L; Zhang L; Huntington KE; El-Deiry WS
    Am J Cancer Res; 2024; 14(9):4523-4536. PubMed ID: 39417197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
    Lin YL; Liau JY; Yu SC; Ou DL; Lin LI; Tseng LH; Chang YL; Yeh KH; Cheng AL
    PLoS One; 2012; 7(11):e50701. PubMed ID: 23209813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRAS
    Miao Q; Deng WQ; Lyu WY; Sun ZT; Fan SR; Qi M; Qiu SH; Zhu YR; Lin JP; Chen MF; Deng LJ
    Free Radic Biol Med; 2023 Aug; 204():301-312. PubMed ID: 37217090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation.
    Budyagan K; Cannon AC; Chatoff A; Snyder NW; Kurimchak AM; Duncan JS; Chernoff J
    Res Sq; 2024 Feb; ():. PubMed ID: 38464238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.
    Ling X; Liu X; Zhong K; Smith N; Prey J; Li F
    Am J Transl Res; 2015; 7(10):1765-81. PubMed ID: 26692923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
    Tejpar S; Celik I; Schlichting M; Sartorius U; Bokemeyer C; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3570-7. PubMed ID: 22734028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.
    Ling X; Wu W; Fan C; Xu C; Liao J; Rich LJ; Huang RY; Repasky EA; Wang X; Li F
    J Exp Clin Cancer Res; 2018 Oct; 37(1):240. PubMed ID: 30285798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.